Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

BACKGROUND: MET-deregulated non-small cell lung cancer represents an urgent clinical need because of the lack of specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET gene alterations, no conclusive data are currently available. Therefor...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimokawa, Mototsugu, Nosaki, Kaname, Seto, Takashi, Ohashi, Kadoaki, Morise, Masahiro, Horinouchi, Hidehito, Sakakibara, Jun, Murakami, Haruyasu, Yano, Seiji, Satouchi, Miyako, Matsumoto, Shingo, Goto, Koichi, Yoh, Kiyotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104510/
https://www.ncbi.nlm.nih.gov/pubmed/32228679
http://dx.doi.org/10.1186/s13063-020-4221-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104510/
https://www.ncbi.nlm.nih.gov/pubmed/32228679
http://dx.doi.org/10.1186/s13063-020-4221-7

Ejemplares similares